Learning objectives: Define the clinical benefit associated with CYP2C19 genotype-guided antiplatelet therapy.

Discuss the opportunities for improving pain management with opiates based on CYP2D6 phenotype.

Session date: 
10/31/2017 - 12:00pm to 1:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Julie A. Johnson, Pharm.D.